Literature DB >> 35223201

A retrospective study on molecular epidemiology trends of carbapenem resistant Enterobacteriaceae in a teaching hospital in Malaysia.

Zhi Xian Kong1, Rina N Karunakaran1, Kartini Abdul Jabar1, Sasheela Ponnampalavanar2, Chun Wie Chong3, Cindy Shuan Ju Teh1.   

Abstract

BACKGROUND: Carbapenem resistant Enterobacteriaceae (CRE) has rapidly disseminated worldwide and has become a global threat to the healthcare system due to its resistance towards "last line" antibiotics. This study aimed to investigate the prevalence of CRE and the resistance mechanism as well as the risk factors associated with in-hospital mortality.
METHODS: A total of 168 CRE strains isolated from a tertiary teaching hospital from 2014-2015 were included in this study. The presence of carbapenemase genes and minimum inhibitory concentration of imipenem, meropenem and colistin were investigated. All carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) strains were characterised by PFGE. The risk factors of patients infected by CRE associated with in-hospital mortality were determined statistically.
RESULTS: The predominant CRE species isolated was K. pneumoniae. The carbapenemases detected were blaOXA-48, blaOXA-232, blaVIM and blaNDM of which blaOXA-48 was the predominant carbapenemase detected among 168 CRE strains. A total of 40 CRE strains harboured two different carbapenemase genes. A total of seven clusters and 48 pulsotypes were identified among 140 CRKp strains. A predominant pulsotype responsible for the transmission from 2014 to 2015 was identified. Univariate statistical analysis identified that the period between CRE isolation and start of appropriate therapy of more than 3 days was statistically associated with in-hospital mortality.
© 2022 Kong et al.

Entities:  

Keywords:  Carbapenem resistant Enterobacteriaceae; Carbapenemase; Epidemiology; Porins; Pulse-field gel electrophoresis

Year:  2022        PMID: 35223201      PMCID: PMC8877335          DOI: 10.7717/peerj.12830

Source DB:  PubMed          Journal:  PeerJ        ISSN: 2167-8359            Impact factor:   2.984


Introduction

Carbapenem resistance is a recognised worldwide threat by the World Health Organisation (WHO). One of the major causes for the emergence of carbapenem resistant pathogens is the overuse of carbapenems in the management of infections caused by extended-spectrum beta-lactamases (ESBLs)-expressing Enterobacteriaceae (Nordmann, Dortet & Poirel, 2012; Slama, 2008; Rahal, 2008). Indeed, given that carbapenem is recommended for the treatment of ESBL infections (Paterson et al., 2004), a steady rise in carbapenem resistance had been recorded in Malaysia with the increasing use of the antibiotics (Institute for Medical Research, 2020). Carbapenem-resistant Klebsiella pneumoniae (CRKp) has persisted and has been gradually rising since its first discovery. For instance, in southeastern United States, a five-fold increase in CRKp infections were recorded from 2008 to 2012 (Thaden et al., 2014). Although carbapenem resistance data is limited, particularly in Southeast Asia, a meta-analysis revealed high estimated carbapenem resistance among Klebsiella spp. in Indonesia, the Philipines, Thailand and Vietnam and among E. coli in Indonesia and Myanmar (Malchione et al., 2019). Among the recorded carbapenem resistant Enterobacteriaceae (CRE), K. pneumoniae is the most prevalent species in Malaysia (Institute for Medical Research, 2020; Zaidah et al., 2017). The widespread distribution of CRKp over different geographical regions is commonly associated with high-risk clones and the acquisition of carbapenemase genes encoded in mobile genetic elements (David et al., 2019; Pitout, Nordmann & Poirel, 2015). In a parallel survey by the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE), a 1.3% increase in population-weighted mean percentage in carbapenem-resistant K. pneumoniae and Escherichia coli (E. coli) was recorded in EU member states from 2011–2014 (Xu et al., 2015; Thaden et al., 2014; European Centre for Disease Prevention and Control, 2020). In Malaysia, the reported carbapenemases that produced by Enterobacteriaceae are blaNDM, blaIMP, blaOXA-48, blaOXA-181 and blaKPC (Hamzan et al., 2015; Wang et al., 2016; Lau et al., 2020). CRE is commonly associated with nosocomial infection. A previous study had identified several factors associated with CRE acquisition such as previous overseas hospitalisation, ICU admission and comorbidities (cardiovascular disease and hematology condition) (Ling et al., 2015). Furthermore, studies had also revealed that usage of mechanical ventilation, presence of central venous catheter and receiving immunosuppressants were associated with mortality (Low et al., 2017; Wang et al., 2016). Understanding the transmission of CRE as well as their resistance mechanism is essential to inform the infection control strategy for containing the spread of CRE. In this study, we investigated the epidemiology of CRE (from 2014 to 2015) in a teaching hospital in Klang Valley, Malaysia. The risk factors associated with mortality among the patients infected or colonised with CRE was also examined.

Materials and Methods

Ethics statement

The medical ethics approval for clinical strains collection and clinical/patients’ data access was obtained from University of Malaya Medical Centre (UMMC) Medical Research Ethics Committee in 2015 (MECID.NO: 20154-1249). In this retrospective study, the informed consent from patient is not required.

Hospital setting and bacterial collection

Strain collection was conducted in UMMC, a tertiary teaching and public hospital with 1,617 beds located in Klang Valley, Malaysia. The Enterobacteriaecae clinical cultures that had been identified as carbapenem resistant in the Medical Microbiology Diagnostic Laboratory (MMDL) of UMMC were retrospectively collected and included in the study. All the included strains were the first CRE isolated and stocked from the patients’ samples between 1st of January of 2014 to 31st of December of 2015. When different sample types received on the same day from a patient had grown CRE, only the first strain per patient which was stocked was included.

Detection of carbapenemase genes among CRE strains

Crude DNA from the CRE strains was prepared using direct boiling method as mentioned by Lim, Teh & Thong (2013). The presence of carbapenemase genes such as blaKPC, blaNDM, blaVIM, blaIMP, blaOXA among the CRE strains were identified by polymerase chain reaction (PCR) as previously described by Naas et al. (2008), Nordmann, Naas & Poirel (2011), Poirel et al. (2011), Poirel et al. (2011), and Poirel et al. (2004) respectively. The amplicons were analysed on 1.0% agarose gel.

Evaluation of antibiotic susceptibility

The MIC value of imipenem, meropenem and colistin among the CRE strains were determined through broth microdilution method according to the Clinical and Laboratory Standard Institute (CLSI) guidelines (Clinical and Laboratory Standards Institute (CLSI), 2021). The MIC breakpoints from the CLSI guidelines was used for imipenem and meropenem (Clinical and Laboratory Standards Institute (CLSI), 2021) while European Committee on Antimicrobial Susceptibility Testing (EUCAST) was used to interpret for the susceptibility of colistin (The European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2021). According to CLSI guidelines, the MIC breakpoints of imipenem and meropenem for susceptible, intermediate, and resistant are ≤1, 2, ≥4 µg/mL respectively. Whilst, according to EUCAST, the MIC breakpoints of colistin for susceptible and resistant are ≤2 and >2 µg/mL respectively. The antibiotic susceptibility of ertapenem was obtained from Medical Microbiology Diagnostic Laboratory (MMDL) of UMMC where the disc diffusion test was carried out. The results were re-interpreted according to CLSI guidelines year of 2021 (Clinical and Laboratory Standards Institute (CLSI), 2021).

Clinical data collection

The clinical details at the time of the CRE isolation were obtained from the patient’s case notes. These details are clearly characterised: (1) A CRE colonisation is defined as the isolation of the microorganism from any non-sterile body sites (usually rectum or perianal area, and respiratory tract/oral cavity, vagina, skin and urine) in the absence of clinical findings of infection (Girmenia et al., 2015). (2) Hospital-acquired infection is defined as infection with positive culture obtained from patients already hospitalised for 48 h or longer (Friedman et al., 2002). Healthcare-associated infection was defined as infection with positive culture obtained at admission or within 48 h or from someone with history of previous hospitalisation or medical procedures (Friedman et al., 2002). (3) Empirical antibiotics is defined as antibiotic that is given to the patients with sign and symptoms of infection before the identification of organisms and susceptibility data were available. (4) Targeted antibiotic is defined as antibiotic that is given to the patients after the culture and susceptibility data is available. (5) Invasive device is defined as a medical device that is introduced into the body, either through a break in the skin or body orifice. This includes central venous line, peripheral line, peripherally inserted central catheter, nasogastric tube, catheter bladder drainage, internal jugular catheter and external ventricular drain. (6) An invasive procedure is defined as one where access to the body is gained via an incision, percutaneous puncture, where instrumentation is used in addition to the puncture needle, or instrumentation via a natural orifice. Invasive procedures include, but are not limited to, endoscopes, catheters, scalpels, scissors, devices, and tubes (Cousins, Blencowe & Blazeby, 2019). (7) Underlying disorder is defined as an acute or chronic comorbidity or condition not related to sepsis that alters short- and/or long-term survival of infectious diseases (Dhainaut et al., 2005). (8) Length of hospitalisation is defined as length of inpatient care, which calculated from the day of admission to the day of discharge. (9) Appropriate therapy is defined as the use of antimicrobial agents with in-vitro activity against the etiologic pathogens (American Thoracic Society, 2005).

Molecular detection of porin genes in Klebsiella spp.

The presence of porin associated genes such as ompK35, ompK36 and ompK37 among the Klebisella spp. were determined by PCR as previously described by Kaczmarek et al. (2006). The PCR product was analysed on 1.0% agarose gel.

Clonal relatedness of carbapenem resistant Klebsiella pneumoniae

The clonal relationship between CRKp strains were investigated using pulse-field gel electrophoresis (PFGE). Plug consisted of extracted whole genomic DNA were digested by XbaI restriction enzyme as previously described by Low et al. (2017). The banding patterns produced were analysed using BioNumerics software (AppliedMaths, Philadelphia, PA, USA). Unweighted Pair Group Method with Arithmetic (UPGMA) were utilised for the cluster analysis with Dice correlation coefficient and 1.5% of tolerance and 1.0% optimisation. The clustering analysis was performed based on the similarity value of ≥80%.

Statistical analysis

The risk factors associated with mortality were deduced statistically using statistical software SPSS 2.0. All continuous variables were expressed as mean ± standard deviation. Nominal variables were evaluated by Fishers’ exact test or chi-square as appropriate while continuous variables were evaluated by student t test or Mann Whitney U test based on the data normality. The analysis was deemed as statistically significant if the P value were less than 0.05.

Results

Identification of CRE samples in patients’ samples

A total of 34 (from 34 patients) and 134 (from 134 patients) CRE strains were retrospectively collected from 2014 and 2015, respectively. K. pneumoniae was the dominant species isolated in both 2014 and 2015, contributed to 73.5% (n = 25) and 85.8% (n = 115) of the total CRE strains in 2014 and 2015, respectively (Table 1). In 2014, a small number of Enterobacter cloacae (n = 4, 11.8%), Escherichia coli (n = 1, 2.9%), Citrobacter freundii (n = 2, 5.9%) and Klebsiella oxytoca (n = 2, 5.9%) were collected. In 2015, the non-Klebsiella species isolated were Escherichia coli (n = 11, 8.3%), Citrobacter freundii (n = 2, 1.5%), Enterobacter cloacae (n = 2, 1.5%), Serratia marcescens (n = 2, 1.5%), Citrobacter koseri (n = 1, 0.7%) and Enterobacter aerogenes (n = 1, 0.7%). Blood (n = 35, 20.8%), urine (n = 29, 17.3%) and tracheal secretion (n = 22, 13.1%) were the common specimens that included in this study (Table 1).
Table 1

Comparison between CRE samples type, identified CRE species and carbapenemase genes detected in 2014 and 2015.

2014 (n =)2015 (n =)
Patient samples
Blood530
Urine821
Tracheal secretion517
Sputum213
Bronchoalveolar fluid34
Pleural fluid10
Pus10
Nasopharyngeal secretion12
Respiratory secretion01
Swab05
Peritoneal fluid swab13
Peritoneal slough swab10
Bone swab02
Backbone suction swab02
Cerebrospinal fluid swab01
Bile swab01
Abdomen fluid swab01
Cyst swab01
Fluid swab01
Sacral swab12
Groin swab11
Stoma swab10
Tissue swab06
Wound swab27
Breast swab01
Pus swab05
Ear swab01
Rectal swab11
Tip swab00
Pigtail aspirate swab01
Chest tube swab01
Catheter swab01
Latex A fluid swab01
Eye swab01
Identified species
Klebsiella pneumoniae 25115
Escherichia coli 111
Enterobacter cloacae 42
Serratia marcescens 02
Citrobacter freundii 22
Citrobacter koseri 01
Klebsiella oxytoca 20
Enterobacter aerogenes 01
Carbapenemase genes
blaNDM1953
blaOXA-4811103
blaOXA-23203
blaVIM01
blaKPC00
blaIMP00
No targeted genes detected513
Loss of porin ( Klebsiella spp.)
ompK35 33
ompK36 35
ompK37 615

Demographic and clinical characteristic of patients

A total of 168 CRE from 168 patients was included in the study; however, 27 patients were excluded from statistical analysis as the data was incomplete in the system. For the 141 sets of patient data extracted from the system, no significant differences in age, races and gender were detected between survivors and non-survivors (Table 2). The mean age of the patients was 54.93 ± 21.42. Chinese were the predominant race (n = 52, 36.9%) followed by Malays (n = 47, 33.3%), Indians (n = 33, 23.4%) and others (n = 9, 6.4%). There were 91 male and 50 female patients. The average length of hospitalisation of patients was more than a month which was 41.15 ± 30.74 days. The survivors recorded a longer duration of hospitalisation. From the 141 CRE isolated, 53.2% (n = 75) were associated with infection while 46.8% (n = 66) were colonisers. The all-cause mortality among patients with CRE isolation (infection/colonisation) was 39.7% (n = 56). Additionally, the duration of CRE isolation and appropriate therapy of more than 3 days was statistically associated with higher mortality.
Table 2

The demographic and clinical data of patients associated with in-hospital all-cause mortality.

VariablesSurvivors (n = 85)Non-survivors (56)P value
Age (years) 54.21 ± 21.9956.02 ± 20.670.610b
Ethnicity
Malay 28190.903
Chinese 32200.816
Indian 19140.716
Other 631.000a
Gender
Male 60310.064
Female 25250.064
Length of hospitalisation (days) 44.98 ± 31.7535.34 ± 28.450.035b
Underlying disorder
Diabetes mellitus 25210.316
Hypertension 32280.147
End-stage renal disease/kidney disease 11210.000
Malignancy 13120.501
Respiratory disease 331.000a
Brain disease 741.000a
Endocrine/metabolite disease 1140.275
Urinary/bladder disease 400.152a
Gastrointestinal disease 840.763a
Bone/joint disease 330.682a
Skin disease 930.363a
Polytrauma 520.703a
Liver/pancreas disease 850.923
Tissue disease 300.277a
Blood disorder 470.114a
Neurological disease 460.195a
Heart disease 550.518a
Pleural effusion 210.518a
Bowel dislocation 101.000a
Rectal prolapse 101.000a
Infection 34280.242
Prostate disease 111.000a
Immune disease 010.397a
Parotitis 010.397a
None 500.157a
Invasive device/procedure 81 (95.3%)56 (100%)0.152a
ICU stay 50 (58.8%)37 (66.1%)0.479a
Colonisation/infection
Colonisation 52 (61.2%)14 (25.0%)0.000
Infection 33 (38.8%)42 (75.0%)0.000
Period between isolation and appropriate therapy for infection cases (n = 75) 0.048
≤3 1510
>3 1832
Carbapenemase
OXA-48 38 (44.7%)24 (42.9%)0.829
NDM 16 (18.8%)11 (19.6%)0.904
OXA-232 1 (1.2%)1 (1.8%)1.000a
OXA-48+NDM 18 (21.2%)16 (28.6%)0.315
No genes 12 (14.1%)4 (7.1%)0.201

Note:

P were obtained using chi-square test unless stated otherwise. P-valuesa was obtained using Fishers’ exact test. P-valuesb was obtained using Mann Whitney U test.

Note: P were obtained using chi-square test unless stated otherwise. P-valuesa was obtained using Fishers’ exact test. P-valuesb was obtained using Mann Whitney U test.

Distribution of carbapenemase genes among CRE strains

The dominant carbapenemase gene detected among the 2014 strains was blaNDM (n = 19, 55.9%) followed by blaOXA-48 (n = 11, 32.4%). In 2015, blaOXA-48 (n = 103, 76.9%) was the predominant carbapenemase gene among the CRE strains, followed by blaNDM (n = 53, 39.6%), blaOXA-232 (n = 3, 2.2%) and blaVIM (n = 1, 0.7%) (Table 1). Both blaIMP and blaKPC were not detected and 18 strains did not harbour any targeted carbapenemase genes. In 2014, 28 (82.4%) strains harboured single carbapenemase gene and one (2.9%) strain harboured dual carbapenemase genes (blaOXA-48+blaNDM). While in 2015, 82 (61.2%) strains harboured single carbapenemase gene and 39 (29.1%) strains harboured dual carbapenemase genes (1 strain with blaOXA-232+blaVIM, 38 strains with blaOXA-48+blaNDM).

Differential sensitivity to carbapenem/colistin among the CRE clinical strains

A high prevalent of resistant to imipenem and meropenem was detected (Table 3). Based on the CLSI guidelines, majority of the strains were either intermediate or resistant to imipenem (82.2%) and meropenem (74.4%). A total of 14 (8.3%) CRE strains exhibited MIC ≤ 1 for both imipenem and meropenem but were mono-resistant/intermediate to ertapenem. Among these 14 strains, 10 strains (71.4%) were K. pneumoniae, 2 strains (14.3%) were E. coli and 1 strain (7.1%) each was Enterobacter cloacae and Citrobacter freundii respectively. In addition, 11 (6.5%) strains were colistin-resistant. Among these 11 strains, 10 strains (90.9%) were K. pneumoniae and 1 strain (9.1%) was Serratia marcescens (Table 3).
Table 3

Sensitivity to imipenem, meropenem and colistin among CRE strains.

Sensitive (≤1 µg/mL) (n =)Intermediate (2 µg/mL) (n =)Resistant (≥4 µg/mL) (n =)
Imipenem
Klebsiella pneumoniae 251996
Escherichia coli 255
Enterobacter cloacae 222
Serratia marcescens 002
Citrobacter freundii 112
Escherichia coli 001
Citrobacter koseri 000
Klebsiella oxytoca 011
Enterobacter aerogenes 001
Meropenem
Klebsiella pneumoniae 301892
Escherichia coli 714
Enterobacter cloacae 213
Serratia marcescens 101
Citrobacter freundii 211
Citrobacter koseri 001
Klebsiella oxytoca 101
Enterobacter aerogenes 010
Sensitive (≤2 µg/mL) (n =) Resistant (>2 µg/mL) (n =)
Colistin
Klebsiella pneumoniae 13010
Escherichia coli 120
Enterobacter cloacae 60
Serratia marcescens 11
Citrobacter freundii 40
Citrobacter koseri 10
Klebsiella oxytoca 20
Enterobacter aerogenes 10

Detection of porin genes associated within Klebsiella spp.

Of the 27 Klebsiella spp. isolated in 2014, nine strains (33%) loss either 1 or 2 porin(s). The number of strains with at least 1 porin loss reduced in 2015 (n = 23; 20%), but 2 strains loss all 3 porins (Table 1).

Molecular characterization of CRKp by PFGE

Based on dendrogram (S1–S3), the 140 CRKp strains were separated into seven major clusters (Cluster I, II, III, IV, V, VI, VII). More than half of the CRKp strains (n = 81, 57.6%) were clustered into Cluster I (11 pulsotypes) followed by Cluster IV (n = 8, 5.7%) and V (n = 7, 5.0%). A total of 48 pulsotypes (XbaI1–XbaI48) have been generated from the PFGE analysis. Among the detected pulsotypes, pulsotype XbaI4. which belonged to Cluster I is the predominant pulsotype that consists of 62 strains (44.3%) which is 100% clonally similar to each other. This pulsotype has been sporadically isolated in January (n = 1), February (n = 1) and April (n = 1) of 2014. However, a steep increment of this pulsotype was observed since December 2014 (n = 5) until the first quarter of 2015 (n = 28). The isolation of this pulsotype was later decreased from 2nd quarter of 2015 (Fig. 1).
Figure 1

The occurrence of pulsotype XbaI4 among CRKp strains from 2014 to 2015.

Sporadic isolation of pulsotype XbaI4 was observed in the first two quarters of 2014. However, there was a steep increment in the isolation of this pulsotype from Q4 2014 to Q1 2015. A gradual decrement in the isolation of pulsotype XbaI4 has been observed from Q2 of 2015.

The occurrence of pulsotype XbaI4 among CRKp strains from 2014 to 2015.

Sporadic isolation of pulsotype XbaI4 was observed in the first two quarters of 2014. However, there was a steep increment in the isolation of this pulsotype from Q4 2014 to Q1 2015. A gradual decrement in the isolation of pulsotype XbaI4 has been observed from Q2 of 2015.

Discussion

K. pneumoniae is a human commensal that colonises the mucosal surfaces such as gastrointestinal tract and respiratory tract (Podschun & Ullmann, 1998). Gastrointestinal tract has been reported as the important reservoir for the transmission and infection of resistant pathogens (Dorman & Short, 2017). The injudicious use of antibiotics has accelerated the development of antibiotic resistance. Over the years, there has been an increase of cases caused by multidrug-resistant K. pneumoniae and the trends of K. pneumoniae strains harbouring resistance genes such as extended spectrum β-lactamase (ESBL) and carbapenemase genes have also been observed (Müller-Schulte et al., 2020; Sirot et al., 1988; Nordmann, Cuzon & Naas, 2009). The propensity for colonisation, transmission, and survival under selection pressure of antibiotics could have enhanced their survival rate, thus contributing to the high infection rate in the hospital setting. The surveillance of the major carbapenemase genes such as blaKPC, blaNDM, blaVIM, blaIMP and blaOXA has been carried out in many countries (Hamzan et al., 2015; Rimrang et al., 2012; Hoang et al., 2013; Karuniawati, Saharman & Lestari, 2013). The reported dominant carbapenemase gene in Singapore and China were blaNDM and blaKPC respectively (Teo et al., 2014; Zhang et al., 2017). However, in our study, blaOXA-48 and blaNDM were the two main carbapenemase genes detected. blaOXA-48 and blaNDM carried on IncL group plasmid and IncFIIK plasmid have been reported. These plasmids have been associated with low fitness burden, high plasmid stability and high transconjugation frequency (Chaalal et al., 2021). In addition, close genetic association between the bleMBL and blaNDM-1 genes has been reported. These two genes are controlled by the same promoter, and this will lead to constitutive expression of blaNDM and bleMBL that encodes a bleomycin resistant protein (BRP). BRF is a functional protein that prevent DNA damage, thus stabilise the plasmid-borne blaNDM. Studies have shown that blaBRF present in both non-clinical and clinical environment. In clinical environment, the medical use of bleomycin as an anticancer agent, contribute to selective pressure that led to further spread of blaNDM in the environment (Dortet, Nordmann & Poirel, 2012). Finally, the dissemination of carbapenemase genes is possibly affected by characteristics of the primary reservoir (which depends on population density, hygiene level, antibiotic selection pressure in that specific area) and population exchange (imported cases from endemic areas) (Nordmann & Poirel, 2014). Several carbapenem resistance mechanisms could be used among the strains without carbapenemase genes. For this group of strains, the resistance could be attributed by permeability defect (porin loss or mutation) coupled with combination of AmpC expression; or ESBL expression; or non-targeted carbapenemase genes in this study (Crowley, Benedí & Doménech-Sánchez, 2002; Shin et al., 2012; García-Fernández et al., 2010). On the other hand, ertapenem mono resistant non-carbapenemase producing K. pneumoniae (EMRNCP-K.p) is also believed to acquire ESBL genes and/or alteration of porins (Chung, Yong & Lee, 2016). In our present study, only a small number of strains showed the loss of porins that could possibly changes the outer membrane permeability. These group of strains were believed to survive poorly compared to other strains. Previous studies had shown that carbapenem resistant bacteria without porins are usually unstable, thus conferred lower fitness, growth and transmission ability in the hospital environment (Nordmann, Dortet & Poirel, 2012). However, it is noteworthy that the presence of porin associated genes may not guarantee the expression. Expression of porin can also be disrupted by insertional inactivation that alters translation resulting in early termination of translation (Chung, Yong & Lee, 2016; Kaczmarek et al., 2006). Majority of the CRKp strains co-harbouring blaNDM and blaOXA-48 belonged to Cluster I. On the other hand, 1 strain that did not harbour any targeted carbapenemase genes also grouped in Cluster I. Hence, it is suggested that strains that shared the same genetic backbone might not utilising the same resistance mechanisms. Although carbapenemase plays an important role in carbapenem resistance, but carbapenemase did not affect the mortality of patients with CRE infection based on statistical analysis. This agrees with previous studies (Daikos et al., 2009). However, there are studies reported the correlations between mortality and severity of underlying diseases as well as the degree of carbapenem resistance (based on MIC value) (Daikos et al., 2009; Daikos et al., 2014). In our study, patients who received definitive treatment at more than 3 days from sample isolation date was significantly associated with mortality compared to patients that received definitive treatment at less or equal than 3 days from sample isolation date. The rapid initiation of appropriate therapy (definitive treatment) has previously been shown to affect in-hospital mortality, but highly dependent on rapid diagnostic that produce accurate and reliable results (Deresinski, 2007; Kumar et al., 2006). In addition, previous studies also suggested the importance of active screening of patients colonised with carbapenemase-producing CRE for implementation of infection control measures, such as isolation, precautions during invasive procedures, patient transport and environment disinfection (Banerjee & Humphries, 2017). Based on the comparison of the finding reported by Low et al. (2017) with our current study, the trend of carbapenem-resistance mechanisms has been changed from year 2013 to 2015. Overall, more resistance mechanisms have been observed in year 2013 compared to 2014 and 2015. For instance, blaKPC-2 and blaIMP have been observed in 2013 but not detected in the latter years. The previous study found that CRKp strains with blaKPC in 2013 were associated with Tn4401b transposon (Low et al., 2017). This isoform has been reported to exhibit lower resistance towards carbapenems when compared to other isoforms (Kitchel et al., 2010). Further, these strains did not belong to the high-risk clones that are responsible for the spread of KPC-harbouring K. pneumoniae such as ST258 and ST11 (Lee et al., 2016), hence it only appeared sporadically. On the other hand, in 2013, only 1 strain co-harbouring blaNDM and blaIMP-8 were found but blaNDM has been the main resistance mechanisms among the strains in 2014 although superseded by blaOXA-48 in 2015. Moreover, the increase of strains that did not harbour the five targeted carbapenemase genes has been observed since 2014. In addition, only blaOXA-48 variant was detected among the strains in 2013 and 2014 but in 2015, 3 blaOXA-232 variants were observed. To date, only 2 blaOXA variants (blaOXA-48, blaOXA-181) have been reported in Malaysia (Lau et al., 2021; Lau et al., 2020). This study shed some lights on the changes of main carbapenem-resistance mechanisms in the hospital within the 3-year period; however, further study is required with more recent patient data set to track the genetic shift of these clinical bacterial strains. The in-hospital mortality rate of CRKp in 2013, 2014 and 2015 were 35.3%, 27.3% and 42.6% respectively. When comparing the CRKp strains among the predominant pulsotype, the in-hospital mortality is increasing from 2013 to 2015 in which the mortality rate of 2013, 2014 and 2015 were 11.1%, 16.7% and 69.6% respectively. The reason behind of the increment could not be concluded based on the collected details. A further study which includes host factors such as white blood cells and nutritional status as well as bacterial virulence factors are needed.

Conclusions

Emergence of CRE was observed in our study setting from 2014 to 2015. The predominant species was K. pneumoniae. The genotypic characterisation of CRKp revealed that the predominant pulsotype had circulated in our setting since 2013. The circulation of this pulsotype with more than one carbapenemase gene could have a negative impact on the management of patients. Hence, this study is important to provide better understanding on the spread of CRE and carbapenemase gene.

Dendrogram generated by UPGMA clustering method using Dice coefficient.

Dendrogram generated by UPGMA clustering method using Dice coefficient. Among the 140 CRKp strains, seven clusters and 48 pulsotypes were generated. Click here for additional data file. Click here for additional data file.
  51 in total

Review 1.  Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.

Authors:  Ritu Banerjee; Romney Humphries
Journal:  Virulence       Date:  2016-05-11       Impact factor: 5.882

2.  Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States.

Authors:  Joshua T Thaden; Sarah S Lewis; Kevin C Hazen; Kirk Huslage; Vance G Fowler; Rebekah W Moehring; Luke F Chen; Constance D Jones; Zack S Moore; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2014-06-20       Impact factor: 3.254

3.  Surveillance trends of carbapenem-resistant Enterobacteriaceae from Singapore, 2010-2013.

Authors:  Jeanette W P Teo; Paul Tan; My-Van La; Prabha Krishnan; Nancy Tee; Tse Hsien Koh; Rama Narayana Deepak; Thean Yen Tan; Roland Jureen; Raymond T P Lin
Journal:  J Glob Antimicrob Resist       Date:  2013-12-06       Impact factor: 4.035

4.  High prevalence of ESBL-producing Klebsiella pneumoniae in clinical samples from central Côte d'Ivoire.

Authors:  Eloise Müller-Schulte; Marie Nonfra Tuo; Chantal Akoua-Koffi; Frieder Schaumburg; Sören L Becker
Journal:  Int J Infect Dis       Date:  2019-11-23       Impact factor: 3.623

5.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

6.  High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe.

Authors:  Frank M Kaczmarek; Fadia Dib-Hajj; Wenchi Shang; Thomas D Gootz
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 7.  Global spread of Carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Thierry Naas; Laurent Poirel
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

8.  High burden of Carbapenem-resistant Enterobacteriaceae (CRE) fecal carriage at a teaching hospital: cost-effectiveness of screening in low-resource setting.

Authors:  Abdul Rahman Zaidah; Nurul Izzah Mohammad; Siti Suraiya; Azian Harun
Journal:  Antimicrob Resist Infect Control       Date:  2017-05-02       Impact factor: 4.887

9.  Loop-mediated isothermal amplification assay for the rapid detection of Staphylococcus aureus.

Authors:  King Ting Lim; Cindy Shuan Ju Teh; Kwai Lin Thong
Journal:  Biomed Res Int       Date:  2013-01-15       Impact factor: 3.411

Review 10.  Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.

Authors:  Thomas G Slama
Journal:  Crit Care       Date:  2008-10-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.